Semax vs VIP

Semax

Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Unlike native ACTH, Semax has been structurally modified to eliminate hormonal activity while retaining and enhancing nootropic and neuroprotective properties. It acts primarily by upregulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, supporting neuronal survival and synaptic plasticity. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been the subject of extensive research. Studies published in Doklady Biological Sciences demonstrated that Semax increased BDNF mRNA expression by up to 1.4-fold in the hippocampus and frontal cortex of rodent models. Research by Ashmarin et al. showed cognitive improvements in attention, memory consolidation, and learning tasks. Clinical investigations in stroke models indicated that Semax use within 6 hours of ischemic events was associated with improved neurological outcomes and reduced infarct progression. Compared to Selank, another Russian-developed nootropic peptide, Semax is more stimulatory and primarily targets cognitive performance and neuroprotection, while Selank leans toward anxiolytic and immunomodulatory effects. Both share favorable safety profiles in preclinical research, but their mechanisms diverge -- Semax through melanocortin pathways and Selank through tuftsin-based immunomodulation. Lyophilized Semax should be stored at -20°C and protected from light. Reconstitute with bacteriostatic water and store at 2-8°C, using within 3-4 weeks. Semax is actively researched by neuroscientists, cognitive psychologists, and stroke researchers investigating neuroprotective interventions.

VIP

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide belonging to the secretin/glucagon superfamily, originally isolated from porcine duodenum by Said and Mutt in 1970. VIP signals through two G-protein coupled receptors, VPAC1 and VPAC2, both of which activate adenylyl cyclase to elevate intracellular cAMP. Widely distributed throughout the central and peripheral nervous systems, VIP functions as a neurotransmitter and neuromodulator with roles in vasodilation, smooth muscle relaxation, exocrine secretion, circadian rhythm regulation, and neuroprotection. Research by Delgado et al. (2004) in Pharmacological Reviews comprehensively characterized VIP's anti-inflammatory properties, demonstrating suppression of TNF-alpha, IL-6, and IL-12 in activated macrophages while upregulating the anti-inflammatory cytokine IL-10. Studies published in the Journal of Neuroscience by Bhatt et al. showed that VIP protected hippocampal neurons from excitotoxic and oxidative damage through VPAC2-mediated cAMP/PKA signaling. Abad et al. in Annals of the New York Academy of Sciences reported that VIP use ameliorated experimental autoimmune encephalomyelitis in murine models, suggesting therapeutic potential in neuroinflammatory conditions. Additional research has shown VIP regulates the suprachiasmatic nucleus master clock, influencing circadian output. Compared to PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), which shares significant structural homology and receptor overlap, VIP has higher selectivity for VPAC receptors and lower affinity for PAC1 receptors. This makes VIP preferred for research specifically targeting VPAC-mediated pathways rather than the broader PAC1-dependent neuroprotective signaling. VIP is sensitive to degradation. Store lyophilized at -20°C. Reconstitute with bacteriostatic water and store at 2-8°C, using within 2-3 weeks. Studied by neuroscientists, immunologists, chronobiologists, and pulmonary researchers investigating airway smooth muscle regulation.

Frequently Asked Questions